A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

This study tests whether combining furmonertinib (a targeted lung cancer drug) with chemotherapy can help patients with non-small cell lung cancer (NSCLC) that has spread to the lining of the brain and spine (leptomeningeal metastasis) — a particularly difficult-to-treat complication. **You may be eligible if...** - You are 18 to 75 years old - You have NSCLC with a specific genetic mutation (EGFR exon 19 deletion or exon 21 L858R mutation), confirmed by biopsy - Cancer has spread to the leptomeninges (the coverings of the brain and spine), confirmed by MRI or spinal fluid testing - Your cancer became resistant to third-generation EGFR-targeted therapies - Your overall health status (ECOG PS) is 0–3 - Expected survival of at least 12 weeks **You may NOT be eligible if...** - You have a cancer type other than lung cancer - You have unresolved significant side effects from prior treatment - You have uncontrolled nausea, vomiting, or severe GI conditions - You have significant liver or kidney problems - You are pregnant (termination strongly advised if pregnancy occurs during the study) Talk to your doctor to see if this trial is right for you.